Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more
Genoway (ALGEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.152x
Based on the latest financial reports, Genoway (ALGEN) has a cash flow conversion efficiency ratio of -0.152x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.80 Million) by net assets (€18.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genoway - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Genoway's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genoway Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genoway ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fideicomiso Irrevocable No. F/3277 en Banco Invex, S. A. Institución de Banca Múltiple, INVEX Grupo
MX:EDUCA18
|
0.027x |
|
Avingtrans Plc
LSE:AVG
|
0.057x |
|
TAEE4F
SA:TAEE4F
|
N/A |
|
Vp plc
LSE:VP
|
0.245x |
|
CPLE3F
SA:CPLE3F
|
N/A |
|
STBP3F
SA:STBP3F
|
N/A |
|
Haleon Pakistan
KAR:HALEON
|
N/A |
|
Strateco Resources Inc
PINK:SRSIF
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Genoway (2009–2024)
The table below shows the annual cash flow conversion efficiency of Genoway from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.57 Million | €5.38 Million | 0.290x | +64.41% |
| 2023-12-31 | €17.38 Million | €3.06 Million | 0.176x | +20.96% |
| 2022-12-31 | €16.17 Million | €2.36 Million | 0.146x | +477.82% |
| 2021-12-31 | €14.56 Million | €-561.34K | -0.039x | -111.14% |
| 2020-12-31 | €9.00 Million | €-164.33K | -0.018x | -110.59% |
| 2019-12-31 | €6.84 Million | €1.18 Million | 0.172x | +60.68% |
| 2018-12-31 | €7.89 Million | €847.03K | 0.107x | +24.32% |
| 2017-12-31 | €7.19 Million | €620.94K | 0.086x | +150.36% |
| 2016-12-31 | €5.26 Million | €-901.83K | -0.171x | -194.23% |
| 2015-12-31 | €4.68 Million | €851.08K | 0.182x | +367.50% |
| 2014-12-31 | €5.15 Million | €200.29K | 0.039x | -76.71% |
| 2013-12-31 | €5.10 Million | €852.87K | 0.167x | +147.59% |
| 2012-12-31 | €4.84 Million | €-1.70 Million | -0.351x | -347.79% |
| 2011-12-31 | €5.23 Million | €741.51K | 0.142x | -28.72% |
| 2010-12-31 | €4.60 Million | €914.07K | 0.199x | -57.80% |
| 2009-12-31 | €3.82 Million | €1.80 Million | 0.471x | -- |